In contrast to the usual type of drug studies it is not our intention to single out specific drug effects, but we are interested in cognitive-psychomotor functioning of psychiatric patients across various periods of therapy, whether due to drug treatment or to underlying mental-affective disorders. 3 groups of psychiatric male patients (7 anxious/inhibited depressives, 7 schizophrenics, 6 patients with psychotic episodes) matched for age (mean = 30 years) and education (no academic trainig) with a group of healthy controls (n = 7) were examined three times during the first 6–8 weeks of their ordinary clinical therapy. The major criterion for the inclusion of a patient next to these diagnostic categories was an initial favorable response to the specified drugs (amitriptyline for the depressives, haloperidol for the schizophrenics, and thioridazine for the patients with psychotic episodes). Each subject was tested in an experimental laboratory with respect to cognitive-psychomotor performance (vigilance, divided attention, choice reaction time), mood, subjective fitness for driving, depression, and paranoia. All groups of patients improved significantly between the acute and the chronic phase. However, healthy controls showed a sharper increase of achievement. While the depressives and the patients with psychotic episodes function on a level of questionable fitness for driving, schizophrenics vary greatly intra- and interindividually, generally on a lower level.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.